GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

Genentech Procures Amphora Oncology Program

  • Genentech reported that it will purchase Amphora's entire program for an unnamed early-stage oncology target with the potential to treat multiple oncology indications.

    The company thus acquired all the intellectual property for the program, including the preclinical lead and several backup series.

    “Amphora's drug discovery engine has produced and is continuing to produce extremely high quality new products,” points out C. Nicholas Hodge, Ph.D., Amphora's CSO and founder. “Amphora has shown that it is capable of moving programs quickly and cost-effectively from screening to proof-of-concept with surprisingly low attrition rates.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »